drugset / Trial / NCT04441385
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Phase 2
Terminated
60 enrolled
Hospital Universitario Infanta Leonor
Hospital Clinic of Barcelona · collabViiV Healthcare · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19).
Timeline
- Start
- 2020-06-26
- Primary completion
- 2021-02-08
- Completion
- 2021-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 300 mg | — |